Inmune Bio (INMB) Cash from Operations (2018 - 2026)
Inmune Bio (INMB) posted Cash from Operations of 3403000.0 for Q1 2026, down 13.43% sequentially from 3000000.0 in Q4 2025, and up 50.13% YoY from 2266673.69 in Q1 2025.
Inmune Bio (INMB) Cash from Operations (2018 - 2026) Analysis & Trends
Inmune Bio has reported Cash from Operations for 9 years, with the latest figure at 3403000.0 in Q1 2026.
- Quarterly Cash from Operations rose 50.13% year-over-year to 3403000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19179000.0 (up 41.43% YoY) and the FY2025 annual result came in at 22600000.0, up 32.34% from the prior year.
- Cash from Operations slipped to 3403000.0 in Q1 2026 per INMB's latest filing, from 3000000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1141000.0 in Q1 2023 and troughed at 11052000.0 in Q4 2024.
- A 5-year average of 5534647.06 and a median of 5401000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations soared 87.13% in 2023, then plunged 555.21% in 2024.
- Over 5 years, Cash from Operations stood at 5695000.0 in 2022, then soared by 39.93% to 3421000.0 in 2023, then sank by 223.06% to 11052000.0 in 2024, then jumped by 72.86% to 3000000.0 in 2025, then slipped by 13.43% to 3403000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 3403000.0, 3000000.0, and 5401000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | -3.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.20 Mn |
| Jun 30, 2026 | -3.20 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -3.00 Mn |
| Dec 31, 2025 | -3.00 Mn |
| Sep 30, 2025 | -5.40 Mn |
| Sep 30, 2025 | -5.40 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Mar 31, 2025 | -6.82 Mn |
| Mar 31, 2025 | -6.82 Mn |
| Dec 31, 2024 | -11.05 Mn |
| Dec 31, 2024 | -11.05 Mn |
| Sep 30, 2024 | -6.99 Mn |
| Sep 30, 2024 | -6.99 Mn |
| Jun 30, 2024 | -7.89 Mn |
| Jun 30, 2024 | -7.89 Mn |
| Mar 31, 2024 | -7.48 Mn |
| Mar 31, 2024 | -7.48 Mn |